Skip to main content
. 2023 Jan 9;16:1065859. doi: 10.3389/fnhum.2022.1065859

TABLE 1.

Baseline age, sex, and migraine data for migraine patients with simple or complex aura and without aura taking migraine preventive medication.

Data Migraine with aura (n = 48) Migraine without aura
(n = 142)
P
(with vs. without aura)
P
(simple vs. complex aura)
Overall
(n = 48)
Simple
(n = 44)
Complex
(n = 4)
Median age, years (IQR) 36.5
(30–49)
33.5
(30-49)
42.0
(38.3-48)
46.0
(36–54.3)
0.012* 0.42
Female sex, n (%) 40 (83.3) 36 (81.8) 4 (100) 119 (83.8) 0.94 NA
Comorbidity presence, n (%) 27 (56.3) 24 (54.5) 3 (75.0) 81 (57.0) 0.94 0.79
Median history of migraine headache, years (IQR) 5.0
(2.1–10)
5.0
(2.1-10)
10
(4-17.5)
6.3
(2–10.5)
0.41 0.34
Chronic migraine subtype, n (%) 17 (35.4) 15 (34.1) 2 (50.0) 54 (38.0) 0.75 0.93
Chronic migraine with MOH 5 (10.4) 4 (9.1) 1 (25.0) 14 (9.9) 0.91 0.89
Median MMDs/MHDs (IQR) 16.6
(8–28)
12
(8-28)
28
(16-28)
14.0
(8–28)
0.99 0.11
Mean MMDs/MHDs 16.6 (9.1) 15.9 (9.0) 24 (8.0) 16.7 (9.0) 0.95 0.09
Median Thai-version MSQ v. 2.1 score (IQR) 60.1
(47.2–72.9)
63.6
(48.3–77.9)
51.5
(45–57.9)
62.9
(48.6–80.4)
0.80 0.25
Median Thai-version MIDAS score (IQR) 4
(0–9.3)
4
(0–9.3)
3
(0–11.3)
5.4
(0–5)
0.16 0.78
Number of preventive medications, n (%)
∙ Monotherapy
∙ Polytherapy

40 (83.3)
8 (16.7)

37 (84.1)
7 (15.9)

3 (75.0)
1 (25.0)

114 (80.3)
28 (19.7)

0.77

0.97
Migraine prevention inhibiting spreading depolarizations used, n (%) 19 (39.6) 19 (43.2) 0 (0) 51 (35.9) 0.78 NA

MIDAS, migraine disability assessment questionnaire; MMDs/MHDs, monthly migraine/headache days; MOH, medication-overuse headache; MSQ, migraine-specific quality of life questionnaire.